{
    "nct_id": "NCT02431468",
    "title": "A Randomized, Double-Blind,Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2018-06-06",
    "description_brief": "This is a randomized double-blind placebo-controlled study comparing different doses of bryostatin for the treatment of moderately severe to severe Alzheimer's disease. The study is 15 weeks in duration, including a safety and efficacy evaluation 30 days after the last dose of study drug.",
    "description_detailed": "This study will enroll 150 moderately severe to severe Alzheimer's disease subjects. Subjects will be randomly assigned 1:1:1 to treatment with two different doses of bryostatin 1 or placebo. The primary analysis will take place after 12 weeks of treatment (7 doses).",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "recruitmentDetails": "Planned: 250 subjects to be screened for a total of 140 subjects randomized 1:1:1 to one of three treatment arms: 20\u03bcg, 40\u03bcg or placebo Actual: 264 subjects were screened. 147 individual subjects were randomized and of those, 141 were dosed with trial drug.",
            "groups": [
                {
                    "id": "FG000",
                    "title": "Bryostatin 1 20ug",
                    "description": "Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.\n\nBryostatin 1: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution."
                },
                {
                    "id": "FG001",
                    "title": "Bryostatin 1 40ug",
                    "description": "Bryostatin 40 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 48 micrograms administered weekly. A total of 7 doses administered over 12 weeks.\n\nBryostatin 1: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution."
                },
                {
                    "id": "FG002",
                    "title": "Placebo",
                    "description": "Placebo administered IV over 45 minutes every other week after 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.\n\nPlacebo: The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution."
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "comment": "Safety Analysis set",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "46"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "47"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "48"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "38"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "29"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "39"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "8"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "18"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "9"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "4"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "5"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "4"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "12"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "2"
                                }
                            ]
                        },
                        {
                            "type": "noncompliance, investigator termination,",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "2"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Bryostatin 1 20ug",
                    "description": "Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.\n\nBryostatin 1: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution."
                },
                {
                    "id": "BG001",
                    "title": "Bryostatin 1 40ug",
                    "description": "Bryostatin 40 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 48 micrograms administered weekly. A total of 7 doses administered over 12 weeks.\n\nBryostatin 1: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution."
                },
                {
                    "id": "BG002",
                    "title": "Placebo",
                    "description": "Placebo administered IV over 45 minutes every other week after 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.\n\nPlacebo: The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution."
                },
                {
                    "id": "BG003",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "46"
                        },
                        {
                            "groupId": "BG001",
                            "value": "47"
                        },
                        {
                            "groupId": "BG002",
                            "value": "48"
                        },
                        {
                            "groupId": "BG003",
                            "value": "141"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "71.2",
                                            "spread": "8.40"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "70.2",
                                            "spread": "7.53"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "73.5",
                                            "spread": "7.68"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "71.7",
                                            "spread": "7.94"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "26"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "22"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "71"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "20"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "25"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "25"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "70"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race/Ethnicity, Customized",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "title": "White",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "42"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "46"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "45"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "133"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "African American",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "3"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "3"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "7"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Asian",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "1"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Region of Enrollment",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "United States",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "46"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "47"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "48"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "141"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Mini Mental State Exam-version 2 (MMSE-2) baseline scores 4-9",
                    "description": "ion, language, and praxis on a scale of 0-30. Lower scores indicate greater cognitive impairment. For this study, subjects were stratified at randomization based on Mini Mental State Exam version 2 (MMSE-2) scores 4-9 (severe cognitive impairment) and 10-15 (moderately severe impairment).",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "18"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "20"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "19"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "57"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Mini Mental State Exam version 2 (MMSE-2) baseline score 10-15",
                    "description": "For this study, subjects were stratified at randomization by Mini Mental State Exam version 2 (MMSE-2) scores 4-9 (severe cognitive impairment) and 10-15 (moderately severe impairment)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "28"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "27"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "29"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "84"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Safety: Number of Subjects With Treatment-emergent Adverse Events and Serious Adverse Events",
                    "description": "Evaluations of adverse events (AEs), serious adverse events (SAEs), Adverse event of special interest - myalgia",
                    "populationDescription": "Safety Analysis Set",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "timeFrame": "Baseline through 30 days post end of treatment (up to Day 107)",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bryostatin 1 20ug",
                            "description": "Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.\n\nBryostatin 1: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution."
                        },
                        {
                            "id": "OG001",
                            "title": "Bryostatin 1 40ug",
                            "description": "Bryostatin 40 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 48 micrograms administered weekly. A total of 7 doses administered over 12 weeks.\n\nBryostatin 1: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution."
                        },
                        {
                            "id": "OG002",
                            "title": "Placebo",
                            "description": "Placebo administered IV over 45 minutes every other week after 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.\n\nPlacebo: The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "46"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "47"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "48"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Number of Subjects w Treatment Emergent AE (TEAE)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "30"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "39"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "28"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "# of Subjects w Treatment Related TEAE",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "17"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "24"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "8"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "# of Subjects w TEAE leading to treatment discont.",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "3"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "2"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "# of Subjects with Serious TEAE",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "3"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "# of Subjects with Treatment Related Serious TEAE",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "# of Subjects w Treatment Emergent Myalgia",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "# of Subjects w Serious Treatment Emergent Myalgia",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "# of Subjects with Fatal TEAE",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Efficacy: Change From Baseline in Severe Impairment Battery (SIB) in the Full Analysis Set (FAS)",
                    "description": "The primary statistical objective for efficacy was to estimate the effect of bryostatin on the mean change in the total SIB score after 12 weeks of treatment, assessed at Week 13 (day 91). Efficacy analyses were conducted according to randomized groups. The SIB is used to assess cognition in subjects with moderate and severe AD. It is divided into nine subscales that include attention, language, orientation, memory, praxis, visuospatial ability, construction, social skills, orienting head to name. Non-verbal responses are allowed, thus decreasing the need for language output. Forty questions are included with a point score range of 0-100. Lower scores indicate greater cognitive impairment.",
                    "populationDescription": "The Full Analysis Set (FAS), consistent with a modified intention-to-treat principle (mITT), was defined as all randomized subjects who received at least one dose of randomized trial medication and who had at least one post-baseline assessment.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "mean change from baseline in SIB score",
                    "timeFrame": "Primary analysis at Week 13 (day 91) after 12 weeks of treatment (up to day 107)",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bryostatin 1 20ug",
                            "description": "Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.\n\nBryostatin 1: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution."
                        },
                        {
                            "id": "OG001",
                            "title": "Bryostatin 1 40ug",
                            "description": "Bryostatin 40 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 48 micrograms administered weekly. A total of 7 doses administered over 12 weeks.\n\nBryostatin 1: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution."
                        },
                        {
                            "id": "OG002",
                            "title": "Placebo",
                            "description": "Placebo administered IV over 45 minutes every other week after 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.\n\nPlacebo: The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "44"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "45"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "46"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Week 13 Full Analysis Set (FAS)",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "38"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "33"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "42"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.6",
                                            "spread": "7.10"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.8",
                                            "spread": "6.58"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-0.4",
                                            "spread": "9.02"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Week 13 Completer Analysis Set (CAS)",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "38"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "33"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "42"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.6",
                                            "spread": "7.10"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.8",
                                            "spread": "6.58"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-0.7",
                                            "spread": "9.02"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "30-Day Followup Full Analysis Set",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "27"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "22"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.3",
                                            "spread": "8.17"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.6",
                                            "spread": "7.51"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-2.7",
                                            "spread": "11.44"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "30-Day Followup Completer Analysis Set",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "27"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "20"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.3",
                                            "spread": "8.17"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.9",
                                            "spread": "7.85"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-2.7",
                                            "spread": "11.44"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001",
                                "OG002"
                            ],
                            "groupDescription": "The primary statistical objective for efficacy was to estimate the effect of bryostatin on the mean change in the Severe Impairment Battery (SIB) after 12 weeks of treatment. A linear model was used for both estimation and significance testing. Primary analysis populations were defined as the Full Analysis Set (FAS) and the Completer Analysis Set (CAS)",
                            "nonInferiorityType": "SUPERIORITY",
                            "pValue": "<0.1",
                            "pValueComment": "LSM and two-sided 80% CI were provided for treatment group differences and estimated endpoint values. A true mean difference in change from baseline in the SIB (one-sided at \u03b1=0.10) of at least 6.5 points in favor of bryostatin groups was assumed.",
                            "statisticalMethod": "t-test, 1 sided",
                            "paramType": "Mean Difference (Net)",
                            "paramValue": "6.5",
                            "ciPctValue": "80",
                            "ciNumSides": "TWO_SIDED"
                        },
                        {
                            "groupIds": [
                                "OG000",
                                "OG001",
                                "OG002"
                            ],
                            "groupDescription": "Change from baseline in SIB in the Completer Analysis Set (CAS)",
                            "nonInferiorityType": "SUPERIORITY",
                            "pValue": "<0.1",
                            "statisticalMethod": "t-test, 1 sided",
                            "paramType": "Mean Difference (Net)",
                            "paramValue": "6.5",
                            "ciPctValue": "80",
                            "ciNumSides": "TWO_SIDED"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Secondary Efficacy Endpoints",
                    "description": "* Change from baseline in the Severe Impairment Battery (SIB) at Weeks 5 and 9. Assesses cognition. Score range 0-100. Lower scores indicate greater cognitive impairment.\n* Change from baseline in Alzheimer Disease Cooperative Study Activities of Daily Living Inventory-Severe Impairment Version (ADCS-ADL-SEV) at Weeks 5, 9,13. A 19-item test of the performance of activities of daily living. Total score range 0-54; lower scores indicate greater functional impairment.\n* Change from baseline in MMSE-2 at Weeks 5, 9 and 13. Tests selected aspects of cognition on a scale of 0-30. Lower scores indicate greater cognitive impairment.\n* Change from baseline in Neuropsychiatric Inventory (NPI) at Weeks 5, 9,13. Caregiver interview assesses 12 behavioral disturbances. Scores range from 0-144; higher scores indicate greater behavioral disturbances.\n* Clinical Global Impression of Improvement (CGI-I) at Weeks 5, 9, 13. A 7-point scale range from (1) very much improved to (7) very much worse.",
                    "populationDescription": "The number of participants analyzed over the course of the study diminished as a result of attrition.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "mean change from baseline",
                    "timeFrame": "Week 5, Week 9, Week 13",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bryostatin 1 20ug",
                            "description": "Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.\n\nBryostatin 1: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution."
                        },
                        {
                            "id": "OG001",
                            "title": "Bryostatin 1 40ug",
                            "description": "Bryostatin 40 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 48 micrograms administered weekly. A total of 7 doses administered over 12 weeks.\n\nBryostatin 1: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution."
                        },
                        {
                            "id": "OG002",
                            "title": "Placebo",
                            "description": "Placebo administered IV over 45 minutes every other week after 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.\n\nPlacebo: The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "46"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "47"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "48"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "SIB Week 5 Full Analysis Set",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "44"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "44"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "46"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.5",
                                            "spread": "7.36"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.8",
                                            "spread": "6.55"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-1.2",
                                            "spread": "10.31"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "SIB Week 5 Completer Analysis Set",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "38"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "32"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "42"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.7",
                                            "spread": "6.02"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.1",
                                            "spread": "5.93"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-1.9",
                                            "spread": "10.33"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "SIB Week 9 Full Analysis Set",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "38"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "38"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "43"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.3",
                                            "spread": "6.87"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.2",
                                            "spread": "6.41"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-0.0",
                                            "spread": "9.91"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "SIB Week 9 Completer Analysis Set",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "37"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "33"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "42"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.2",
                                            "spread": "6.93"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.1",
                                            "spread": "6.06"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-0.1",
                                            "spread": "10.0"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Week 5 ADCS-ADL-SIV : FAS",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "43"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "43"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "48"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.3",
                                            "spread": "4.16"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.1",
                                            "spread": "6.31"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-0.7",
                                            "spread": "5.07"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Week 9 ADCS-ADL-SIV : FAS",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "37"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "38"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "43"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.4",
                                            "spread": "4.68"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.5",
                                            "spread": "5.05"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-1.3",
                                            "spread": "4.07"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Week 13 ADCS-ADL-SIV : FAS",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "37"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "33"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "42"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.7",
                                            "spread": "4.59"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.0",
                                            "spread": "4.86"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-2.2",
                                            "spread": "5.28"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Week 5 MMSE-2: FAS",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "44"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "44"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "46"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.4",
                                            "spread": "2.43"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.1",
                                            "spread": "2.79"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-0.1",
                                            "spread": "2.40"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Week 9 MMSE-2: FAS",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "38"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "38"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "43"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.8",
                                            "spread": "2.98"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.3",
                                            "spread": "3.01"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "0.5",
                                            "spread": "3.11"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Week 13 MMSE-2: FAS",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "38"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "33"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "42"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.5",
                                            "spread": "3.09"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.3",
                                            "spread": "2.54"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-0.2",
                                            "spread": "3.49"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Week 5 Neuropsychiatric Inventory (NPI): FAS",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "41"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "41"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "44"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.5",
                                            "spread": "11.72"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1.7",
                                            "spread": "12.03"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-2.4",
                                            "spread": "10.31"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Week 9 Neuropsychiatric Inventory (NPI): FAS",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "37"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "34"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "41"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.5",
                                            "spread": "11.97"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.0",
                                            "spread": "8.33"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-2.5",
                                            "spread": "11.05"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Week 13 Neuropsychiatric Inventory (NPI): FAS",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "37"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "32"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "39"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.0",
                                            "spread": "12.62"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.0",
                                            "spread": "11.94"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "1.0",
                                            "spread": "10.45"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "POST_HOC",
                    "title": "Severe Impairment Battery (SIB) Scores by Memantine Use at Baseline",
                    "description": "Change from baseline in SIB score was compared between subjects receiving concurrent treatment with memantine and subjects not being treated with memantine.",
                    "populationDescription": "Participants in the 3 treatment groups were further sorted by use of memantine. The number of participants in each category at each timepoint is noted. Attrition occurred through the course of the study.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "mean change from baseline in SIB score",
                    "timeFrame": "Assessments at weeks 5, 9, 13, and 30 days after end of treatment (up to day 107).",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bryostatin 1 20ug With Memantine",
                            "description": "Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.\n\nBryostatin 1: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution."
                        },
                        {
                            "id": "OG001",
                            "title": "Bryostatin 1 40ug With Memantine",
                            "description": "Bryostatin 40 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 48 micrograms administered weekly. A total of 7 doses administered over 12 weeks.\n\nBryostatin 1: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution."
                        },
                        {
                            "id": "OG002",
                            "title": "Placebo With Memantine",
                            "description": "Placebo administered IV over 45 minutes every other week after 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.\n\nPlacebo: The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution."
                        },
                        {
                            "id": "OG003",
                            "title": "Bryostatin 1 20ug Without Memantine",
                            "description": "Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks."
                        },
                        {
                            "id": "OG004",
                            "title": "Bryostatin 1 40ug Without Memantine",
                            "description": "Bryostatin 40 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 48 micrograms administered weekly. A total of 7 doses administered over 12 weeks."
                        },
                        {
                            "id": "OG005",
                            "title": "Placebo Without Memantine",
                            "description": "Placebo administered IV over 45 minutes every other week after 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "26"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "37"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "31"
                                },
                                {
                                    "groupId": "OG003",
                                    "value": "18"
                                },
                                {
                                    "groupId": "OG004",
                                    "value": "8"
                                },
                                {
                                    "groupId": "OG005",
                                    "value": "15"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Week 5 SIB change from Baseline",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "26"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "37"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "31"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "18"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "7"
                                        },
                                        {
                                            "groupId": "OG005",
                                            "value": "15"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.1",
                                            "spread": "8.11"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.6",
                                            "spread": "6.50"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-1.3",
                                            "spread": "10.50"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "3.4",
                                            "spread": "5.75"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "3.9",
                                            "spread": "4.98"
                                        },
                                        {
                                            "groupId": "OG005",
                                            "value": "-1.2",
                                            "spread": "10.26"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Week 9 SIB change from Baseline",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "31"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "29"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "15"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "7"
                                        },
                                        {
                                            "groupId": "OG005",
                                            "value": "15"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.1",
                                            "spread": "6.52"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.6",
                                            "spread": "6.88"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-0.4",
                                            "spread": "11.01"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "3.5",
                                            "spread": "7.04"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "2.0",
                                            "spread": "3.16"
                                        },
                                        {
                                            "groupId": "OG005",
                                            "value": "0.8",
                                            "spread": "7.44"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Week 13 SIB change from Baseline",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "22"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "26"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "28"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "16"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "7"
                                        },
                                        {
                                            "groupId": "OG005",
                                            "value": "14"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.5",
                                            "spread": "6.51"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.1",
                                            "spread": "6.61"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-0.5",
                                            "spread": "10.03"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "4.5",
                                            "spread": "7.01"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "3.9",
                                            "spread": "5.84"
                                        },
                                        {
                                            "groupId": "OG005",
                                            "value": "-1.1",
                                            "spread": "6.89"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "30-day Followup SIB change from Baseline",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "15"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "20"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "18"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "12"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "OG005",
                                            "value": "11"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.1",
                                            "spread": "8.39"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.3",
                                            "spread": "7.71"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-3.8",
                                            "spread": "13.10"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "6.7",
                                            "spread": "5.58"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "4.0",
                                            "spread": "5.66"
                                        },
                                        {
                                            "groupId": "OG005",
                                            "value": "-1.0",
                                            "spread": "8.31"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "timeFrame": "Adverse event data was collected beginning at the time of informed consent until the 30-day post treatment visit. For subjects enrolled under protocol versions 1 (17 Apr 2015) and 2 (20 Jan 2016), this collection occurred from Day -21 through Day 198 for subjects completing the study. For subjects enrolled under protocol version 3 (15 Jul 2016) this collection occurred from Day -28 through Day 105.",
            "description": "In addition to the standard defined adverse events, an adverse event of special interest was defined in this study; myalgia.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Bryostatin 1 20ug",
                    "description": "Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.\n\nBryostatin 1: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 46,
                    "seriousNumAffected": 2,
                    "seriousNumAtRisk": 46,
                    "otherNumAffected": 21,
                    "otherNumAtRisk": 46
                },
                {
                    "id": "EG001",
                    "title": "Bryostatin 1 40ug",
                    "description": "Bryostatin 40 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 48 micrograms administered weekly. A total of 7 doses administered over 12 weeks.\n\nBryostatin 1: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.",
                    "deathsNumAffected": 1,
                    "deathsNumAtRisk": 47,
                    "seriousNumAffected": 6,
                    "seriousNumAtRisk": 47,
                    "otherNumAffected": 46,
                    "otherNumAtRisk": 47
                },
                {
                    "id": "EG002",
                    "title": "Placebo",
                    "description": "Placebo administered IV over 45 minutes every other week after 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.\n\nPlacebo: The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 48,
                    "seriousNumAffected": 4,
                    "seriousNumAtRisk": 48,
                    "otherNumAffected": 12,
                    "otherNumAtRisk": 48
                }
            ],
            "seriousEvents": [
                {
                    "term": "Pneumonia",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Ovarian cancer",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Confusion postoperative",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Bladder cancer",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Atrial fibrillation",
                    "organSystem": "Cardiac disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Infusion Site Pain",
                    "organSystem": "General disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Dementia Alzheimer's Type",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Diabetic ketoacidosis",
                    "organSystem": "Metabolism and nutrition disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Infusion site cellulitis",
                    "organSystem": "Infections and infestations",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Seizure",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Syncope",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 48
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Myalgia",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 6,
                            "numAffected": 4,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Diarrhea",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 6,
                            "numAffected": 5,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Infusion site extravasation",
                    "organSystem": "General disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 4,
                            "numAffected": 3,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Fatigue",
                    "organSystem": "General disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Infusion site pain",
                    "organSystem": "General disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Urinary tract infection",
                    "organSystem": "Infections and infestations",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Infusion site cellulitis",
                    "organSystem": "Infections and infestations",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Fall",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 5,
                            "numAffected": 4,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Contusion",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Weight decreased",
                    "organSystem": "Investigations",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Decreased appetite",
                    "organSystem": "Metabolism and nutrition disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 6,
                            "numAffected": 6,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Headache",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 4,
                            "numAffected": 3,
                            "numAtRisk": 46
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 47
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 48
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "GT60",
                "restrictiveAgreement": true
            },
            "pointOfContact": {
                "title": "David Crockford, Vice President, Regulatory Affairs",
                "organization": "Neurotrope BioScience, Inc.",
                "email": "dcrockford@neurotropebioscience.com",
                "phone": "(973)242-0005"
            }
        }
    },
    "target_category": "disease-targeted small molecule",
    "drug": [
        "bryostatin (bryostatin-1)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The investigational agent is bryostatin (bryostatin-1), a small-molecule marine-derived macrocyclic lactone that activates protein kinase C (PKC) isoforms (including PKC\u03b5) and has been shown preclinically to induce synaptogenesis, increase \u03b1-secretase activity (reducing A\u03b2), and reduce hyperphosphorylated tau \u2014 i.e., it modulates Alzheimer\u2019s disease\u2013relevant biology rather than being solely a symptomatic agent. \ue200cite\ue202turn0search6\ue202turn0search7\ue202turn0search4\ue201",
        "Act: The provided trial title/description matches an intravenous randomized double-blind placebo-controlled Phase 2 study of bryostatin in moderate\u2013severe AD (safety/tolerability/efficacy over ~15 weeks). This confirms the drug and indication for which we classified the trial. \ue200cite\ue202turn0search6\ue202turn0search0\ue201",
        "Drug classification evidence: Bryostatin-1 is described in the literature as a PKC activator that facilitates long-term potentiation and synaptogenesis (mechanistic electrophysiology and cellular work), consistent with a small-molecule pharmacologic modulator rather than a biologic (monoclonal antibody or vaccine). \ue200cite\ue202turn0search1\ue202turn0search4\ue201",
        "Reflect: Given the developer definitions, bryostatin best fits 'disease-targeted small molecule' because (a) it is a small molecule (not a biologic), and (b) its documented actions target Alzheimer\u2019s-related pathology and synaptic restoration (anti-A\u03b2 oligomers, anti-tau, synaptogenic effects) rather than being solely a generic symptomatic cognitive enhancer or a neuropsychiatric symptom treatment. The Phase 2 trial tests cognitive/efficacy outcomes consistent with disease-directed therapeutic intent. \ue200cite\ue202turn0search6\ue202turn0search7\ue201",
        "Web-search sources used (key results): 1) Phase II randomized double\u2011blind trial report (safety/tolerability/efficacy of bryostatin in advanced AD). \ue200cite\ue202turn0search6\ue201 2) Preclinical/clinical summaries showing bryostatin activates PKC (PKC\u03b5), promotes synaptogenesis and LTP. \ue200cite\ue202turn0search1\ue202turn0search4\ue201 3) Animal-model data showing bryostatin activation increases \u03b1\u2011secretase (sAPP\u03b1) and reduces A\u03b240/A\u03b242. \ue200cite\ue202turn0search7\ue201"
    ],
    "agent_type": "M) Synaptic Plasticity/Neuroprotection",
    "explanation_agent": [
        "Reason: The investigational drug is bryostatin-1, a small-molecule activator of protein kinase C (PKC), with emphasis on PKC\u03b5; its preclinical and clinical literature emphasizes promotion of synaptogenesis, facilitation of long\u2011term potentiation (LTP), and neurorestorative effects\u2014i.e., actions on synaptic plasticity and neuroprotection rather than a purely symptomatic mechanism. \ue200cite\ue202turn0search1\ue202turn0search7\ue202turn0search4\ue201",
        "Act: Extracted details \u2014 drug: bryostatin (bryostatin\u20111); primary molecular action: PKC (including PKC\u03b5) activation; reported effects: increased synaptogenesis/PSD\u201195 and facilitation of LTP, increased \u03b1\u2011secretase (sAPP\u03b1) and reduced A\u03b2, and reduction of hyperphosphorylated tau; clinical testing: Phase II randomized double\u2011blind trial in moderate\u2011to\u2011severe AD. Key supporting sources: Phase II clinical report and preclinical/physiology studies. \ue200cite\ue202turn0search0\ue202turn0search4\ue202turn0search1\ue202turn0search7\ue201",
        "Reflect: Although bryostatin has reported effects on A\u03b2 processing and tau phosphorylation (which could map to Proteostasis/Proteinopathies, CADRO I), the drug\u2019s canonical and proximate mechanism in the AD literature is activation of PKC with downstream synaptogenic and LTP\u2011promoting/neuroprotective effects. The most specific CADRO category that matches these primary actions is M) Synaptic Plasticity/Neuroprotection. I considered multi\u2011target (R) but the literature frames bryostatin primarily as a PKC\u2011mediated synaptic/neuroprotective agent, so M is the best single-category fit. \ue200cite\ue202turn0search1\ue202turn0search7\ue201",
        "Web search results (key sources cited above):",
        "- Phase II randomized double\u2011blind trial (J Alzheimers Dis. 2019) \u2014 safety/tolerability/efficacy of bryostatin in moderate\u2013severe AD. \ue200cite\ue202turn0search0\ue201",
        "- Phase IIa / expanded access clinical report showing PKC\u03b5 activation and acute MMSE signal. \ue200cite\ue202turn0search4\ue201",
        "- PNAS preclinical study showing bryostatin enhances \u03b1\u2011secretase (sAPP\u03b1), reduces A\u03b240/A\u03b242 in transgenic mice. \ue200cite\ue202turn0search1\ue201",
        "- Electrophysiology study showing bryostatin facilitates hippocampal LTP via PKC\u03b1/PKC\u03b5. \ue200cite\ue202turn0search7\ue201",
        "- Alzforum summary of clinical and preclinical data for bryostatin\u20111. \ue200cite\ue202turn0search2\ue201"
    ]
}